Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Lanz, Christian ^a   Mattsson, Johan ^b   Soydaner, Umut ^c   Brenneisen, Rudolf ^c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c Apotheke Dr Lanz ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; DRONABINOL; MEDICAL CANNABIS;

ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DECARBOXYLATION; DRUG RELEASE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MASS SPECTROMETRY; PATIENT SAFETY; VALIDATION STUDY; VAPORIZATION; VAPORIZER; COMPARATIVE STUDY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MASS FRAGMENTOGRAPHY; NEBULIZER; PROCEDURES;

ADMINISTRATION, INHALATION; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MEDICAL MARIJUANA; NEBULIZERS AND VAPORIZERS;

EID: 84958214706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147286     Document Type: Article

References (34)

1. Li H-L. An archaeological and historical account of cannabis in China. Econ Bot 1973; 28: 437-448.
2. O'Shaughnessy WB. On the preparations of the Indian hemp (Cannabis indica); their effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases. Trans Med Phys Soc Bengal 1838-1840: 421-461.
3. Mechoulam R, Shvo Y. Hashish. I. The structure of cannabidiol. Tetrahedron 1963; 19: 2073-2078. PMID: 5879214
4. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86: 1646-1647.
5. Radwan MM, Elsohly MA, Slade D, Ahmed SA, Wilson L, El-Alfy AT, et al. Non-cannabinoid constituents from a high potency Cannabis sativa variety. Phytochemistry 2008; 69: 2627-2633. doi: 10.1016/j. phytochem.2008.07.010 PMID: 18774146
6. Radwan MM, Elsohly MA, Slade D, Ahmed SA, Khan IA, Ross SA. Biologically active cannabinoids from high-potency Cannabis sativa. J Nat Prod 2009; 72: 906-911. doi: 10.1021/np900067k PMID: 19344127
7. Hanus LO. Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev 2009; 29: 213-271. doi: 10.1002/med.20135 PMID: 18777572
8. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988; 34: 605-613. PMID: 2848184
9. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564. PMID: 2165569
10. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65. PMID: 7689702
11. Atakan Z. 2012. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2: 241-254. doi: 10.1177/2045125312457586 PMID: 23983983
12. Grotenhermen F, Muller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Dtsch Arztebl Int 2012; 109: 495-501. PMID: 23008748
13. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006; 105: 1-25. PMID: 16540272
14. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986; 38: 151-178. PMID: 3529128
15. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003; 2: 291-298. PMID: 12849183
16. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 2011; 163: 1344-1364. doi: 10.1111/j.1476-5381.2011.01238.x PMID: 21749363
17. Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D. Neuroprotection in experimental autoimmune encephalomyelitis and progressive multiple sclerosis by cannabis-based cannabinoids. J Neuroimmune Pharmacol 2015; 10: 281-292. doi: 10.1007/s11481-014-9575-8 PMID: 25537576
18. Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006; 66: 234-246. PMID: 16209908
19. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers 2007; 4: 1678-1692. PMID: 17712814
20. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, et al. Pharmacokinetics and metabolism of delta-1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38: 21-43. PMID: 3012605
21. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001; 178: 101-106. PMID: 11157422
22. Hazekamp A, Ruhaak R, Zuurman L, van Gerven J, Verpoorte R. Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol. J Pharm Sci 2006; 95: 1308-1317. PMID: 16637053
23. Gieringer D. Marijuana research: waterpipe study. MAPS 1996; 6: 59-66.
24. Gieringer D. Cannabis vaporization: a promising strategy for smoke harm reduction. J Cannabis Ther 2001; 1: 153-170.
25. Gieringer D. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther 2004; 4: 7-27.
26. Fischedick J, Van Der Kooy F, Verpoorte R. Cannabinoid receptor 1 binding activity and quantitative analysis of Cannabis sativa L. smoke and vapor. Chem Pharm Bull (Tokyo) 2010; 58: 201-207.
27. Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised Cannabis sativa. Inhal Toxicol 2009; 21: 1108-1112. doi: 10.3109/08958370902748559 PMID: 19852551
28. Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther 2007; 82: 572-578. PMID: 17429350
29. Naef M, Russmann S, Petersen-Felix S, Brenneisen R. Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans. J Pharm Sci 2004; 93: 1176-1184. PMID: 15067694
30. Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, et al. Effect of intrapulmonary tetrahydrocannabinol administration in humans. J Psychopharmacol 2008; 22: 707-716. doi: 10.1177/0269881108089581 PMID: 18515447
31. Earleywine M, Barnwell SS. Decreased respiratory symptoms in cannabis users who vaporize. Harm Reduct J 2007; 4: 11. PMID: 17437626
32. Van Dam NT, Earleywine M. Pulmonary function in cannabis users: support for a clinical trial of the vaporizer. Int J Drug Policy 2010; 21: 511-513. doi: 10.1016/j.drugpo.2010.04.001 PMID: 20451365
33. Food and Drug Administration. Guidance for industry-Bioanalytical method validation. U.S. Department of Health and Human Services, Rockville, MD, 2001. Available at http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
34. Dussy FE, Hamberg C, Luginbuhl M, Schwerzmann T, Briellmann TA. Isolation of delta-9-THCA-A from hemp and analytical aspects concerning the determination of delta-9-THC in cannabis products. Forensic Sci Int 2005; 149: 3-10. PMID: 15734104